BTBD11

Across TCGA pan-cancer cohorts, BTBD11 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of BTBD11’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where BTBD11 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BTBD11 is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

LSCC, HNSC, and CCRCC are the cancer types where BTBD11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTBD11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+0.690	<.001	8	view →
HNSC	All	All	−0.220	<.001	8	view →
CCRCC	Male	All	−0.892	<.001	4	view →
PDAC	All	All	+0.338	.016	4	view →
LUAD	All	All	−0.568	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

BTBD11–LSCC

Open the LSCC breakdown →